Epinastine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Epinastine: From Allergic Disease to Allergic Urticaria
One-Sentence Summary
Epinastine is a second-generation H1-antihistamine/mast-cell stabiliser, historically marketed abroad (as Alesion) for allergic rhinitis, atopic dermatitis and allergic conjunctivitis. The TxGNN model’s top-ranked candidate for this drug (rosacea conjunctivitis, 99.57%) is unsupported by any trial or literature and has therefore not been carried forward; the best-supported repurposing signal is instead Allergic Urticaria, backed by 2 post-marketing surveillance studies (n=3,793 and n=2,001) and 11 publications, including two randomised comparisons of antihistamine wheal-and-flare suppression.
Note on candidate selection: TxGNN’s raw #1-ranked prediction for epinastine was rosacea conjunctivitis (score 99.57%), but the evidence pack itself flags this as a purely computational link with no supporting trials, no literature, and a weak mechanistic rationale (Hold). Allergic urticaria (rank 2, score 99.28%) is used as the primary indication in this report because it is the only candidate with actual clinical and literature support and a decision stage beyond S0.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file for this market (epinastine is unlicensed here; no taiwan_regulatory.licenses entries exist). Published literature describes established use abroad, as “Alesion”, for allergic rhinitis, atopic dermatitis/eczema, and allergic conjunctivitis. |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.28% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action data was not returned in this evidence pack (original_moa: [Data Gap], tracked as gap DG002). Based on the literature retrieved alongside this candidate, epinastine is a potent H1-receptor antagonist that also stabilises mast cells and suppresses antileukotriene, anti-PAF and antibradykinin pathways, and inhibits mediator release from mast cells and eosinophils (PMID 12845334). This is a well-characterised, class-typical antiallergic profile shared with other second-generation antihistamines.
Allergic urticaria is a histamine/mast-cell-mediated condition — the pathology is essentially the same wheal-and-flare mechanism that H1-antagonists like epinastine are designed to block. Critically, the trial-level rationale in this pack notes that Alesion (epinastine) is already approved in Japan for urticaria, meaning this is best understood as a label-extension into a market where the drug is not yet authorised, rather than a novel mechanistic hypothesis. This substantially de-risks the pharmacological plausibility compared with a genuinely new mechanism-of-action claim.
By contrast, the model’s highest-scoring candidate (rosacea conjunctivitis) does not share this histamine-driven pathology — rosacea-associated conjunctivitis is primarily vascular and sebaceous in origin — which is consistent with the complete absence of supporting trials or literature for that candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02238236 | N/A (Post-marketing surveillance) | Completed | 3,793 | Real-world safety/efficacy of Alesion® Dry Syrup in Japanese paediatric patients with allergic rhinitis, eczema/dermatitis, urticaria and pruritus. |
| NCT02238223 | N/A (Post-marketing surveillance) | Completed | 2,001 | Real-world safety/efficacy of Alesion® Tablet under updated treatment guidance for allergic rhinitis, asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching. |
Both studies are large post-marketing surveillance programmes rather than randomised controlled trials — they support real-world usage experience and safety signal detection but cannot establish efficacy causation on their own.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10442525 | 1999 | RCT | Allergy | Double-blind, single-dose, crossover study; epinastine (with cetirizine, ebastine, fexofenadine, terfenadine, loratadine) suppressed histamine-induced wheal-and-flare for 24h vs placebo. |
| 19558008 | 2009 | RCT | Ann Allergy Asthma Immunol | Compared first- vs second-generation antihistamines in suppressing histamine- and allergen-induced skin reactions, the core mechanism underlying urticaria control. |
| 12845334 | 2000 | Review | Drugs of Today | Overview of epinastine’s antihistaminic, antileukotriene, anti-PAF and antibradykinin activity, and mast-cell/eosinophil mediator inhibition. |
| 15510239 | 2004 | Review | Drugs of Today | Epinastine’s role across atopic conditions (allergic rhinitis, atopic eczema, allergic conjunctivitis, asthma) and comparative side-effect profile. |
| 11829715 | 2002 | Review | Expert Opin Investig Drugs | Discusses shared histamine-driven mechanisms across allergic rhinitis, asthma, allergic conjunctivitis and chronic idiopathic urticaria (CIU). |
| 18597008 | 2008 | Cohort | Methods Find Exp Clin Pharmacol | Large-scale surveillance (n=1,742) of sedative profiles across H1-antihistamines including epinastine, relevant to tolerability. |
| 34387278 | 2021 | Receptor pharmacology | Curr Opin Allergy Clin Immunol | Reviews receptor-affinity profiles of ophthalmic/systemic antiallergic agents, contextualising epinastine’s target engagement. |
| 29723372 | 2018 | Comparative pharmacology study | An Bras Dermatol | Compared wheal-and-flare suppression by first-generation antihistamines marketed in Brazil, including epinastine’s class comparators. |
| 10876807 | 2000 | Pharmacology review | Nihon Yakurigaku Zasshi | Cetirizine pharmacology paper benchmarking wheal-response inhibition against terfenadine, loratadine, epinastine and ebastine. |
| 18524543 | 2008 | Immunology study | J Dermatol Sci | Examines antihistamine regulatory effects on dendritic cells/T cells relevant to urticaria and atopic dermatitis pathogenesis. |
UK Market Information
Epinastine currently holds no marketing authorisation in this jurisdiction (market_status: Not marketed / Not marketed; total_licenses: 0). No product entries are available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Formal warnings, contraindications and drug-interaction data for epinastine were not available in this evidence pack (data gap DG001, flagged Blocking — required before any safety pre-assessment can proceed).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Allergic urticaria has a mechanistically coherent, class-consistent rationale, supported by two large post-marketing surveillance programmes and RCT-level evidence for the underlying wheal-and-flare mechanism, plus an existing overseas approval (Japan, Alesion) for this exact indication — this is a label-extension case rather than a speculative new mechanism.
To proceed, the following is needed:
- Formal MOA/pharmacological classification from DrugBank (gap DG002)
- TFDA-equivalent product warnings, contraindications and DDI profile — currently blocking (gap DG001)
- A locally-run or bridging clinical study, since existing evidence is PMS/overseas RCT data rather than a local pivotal trial
- Formal review of route/formulation compatibility (oral vs ophthalmic) for the urticaria indication, which was not resolved in this evidence pack
- A regulatory pathway assessment for seeking marketing authorisation, given epinastine is currently unlicensed in this market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.